Analysis of Typical Problems of Moderate Change in Post-approval Chemical Drugs

被引：0
|
作者：
Yuan, Jianlong [1 ]
Zhang, Lingna [1 ]
Chen, Qingyu [1 ]
Huang, Rongzhen [1 ]
机构：
[1] Fujian Center for Drug Evaluation and Monitoring, Fuzhou,350003, China
来源：
Chinese Journal of Pharmaceuticals | 2023年 / 54卷 / 10期
关键词：
D O I：
10.16522/j.cnki.cjph.2023.10.017
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1517 / 1520
相关论文
共 50 条
  • [21] Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-Approval Data
    Cook, S.
    Giovannoni, G.
    Leist, T.
    Comi, G.
    Syed, S.
    Nolting, A.
    Damian, D.
    Schick, R.
    Jack, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP65 - NP66
  • [22] Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data
    Cook, S.
    Giovannoni, G.
    Leist, T.
    Comi, G.
    Syed, S.
    Nolting, A.
    Damian, D.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 767 - 768
  • [23] Updated Safety Of Cladribine Tablets In The Treatment Of Patients With Multiple Sclerosis: Integrated Safety Analysis And Post-approval Data
    Cook, S.
    Giovannoni, G.
    Leist, T. P.
    Comi, G.
    Syed, S.
    Nolting, A.
    Damian, D.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 52 - 52
  • [24] Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data
    Cook, Stuart
    Giovannoni, Gavin
    Leist, Thomas
    Comi, Giancarlo
    Syed, Sana
    Nolting, Axel
    Damian, Doris
    Schick, Regina
    NEUROLOGY, 2020, 94 (15)
  • [25] Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-Approval Data
    Cook, S.
    Giovannoni, G.
    Leist, T.
    Comi, G.
    Syed, S.
    Noltine, A.
    Damian, D.
    Schick, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 327 - 328
  • [26] Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability
    Vinther, Anders
    Ramnarine, Emma
    Gastineau, Thierry
    O'Brien, Laura
    Brehm, Oliver
    Fryrear, David
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (03) : 433 - 442
  • [27] Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability
    Anders Vinther
    Emma Ramnarine
    Thierry Gastineau
    Laura O’Brien
    Oliver Brehm
    David Fryrear
    Therapeutic Innovation & Regulatory Science, 2024, 58 : 433 - 442
  • [28] Analysis of safety specifications in risk management plan at the time of drug approval and addition of clinically significant adverse reactions in the package insert post-approval in Japan
    Saito, Rieko
    Miyazaki, Seiko
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (04):
  • [29] Development of a guidance for including patient-reported outcomes (PROs) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER).
    Basch, E. M.
    Abernethy, A. P.
    Mullins, C. D.
    Tiglao, M. R.
    Tunis, S. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED OUTCOMES (PROS) IN POST-APPROVAL CLINICAL TRIALS OF ONCOLOGY DRUGS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)
    Basch, E. M.
    Abernethy, A.
    Mullins, C. D.
    Tiglao, M. R.
    Tunis, S. R.
    VALUE IN HEALTH, 2011, 14 (03) : A10 - A10
12345